Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C.

@article{Rosa2006DosedependentAG,
  title={Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C.},
  author={Francesco Giuseppe de Rosa and Olivia Bargiacchi and Sabrina Audagnotto and Silvia Garazzino and Giuseppe Cariti and Riccardo Raiteri and Giovanni di Perri},
  journal={The Journal of antimicrobial chemotherapy},
  year={2006},
  volume={57 2},
  pages={360-3}
}
OBJECTIVES The optimal regimen for acute hepatitis C (AHC) is considered to be a 24 week treatment with interferon (IFN) alpha-2b. A 24 week treatment with pegylated IFN (PEG-IFN) alpha-2b is also effective. This study was designed to assess response rates to a 12 week regimen of PEG-IFN alpha-2b. PATIENTS AND METHODS Patients with AHC were treated with… CONTINUE READING